(Birmingham, Alabama, May 21st, 2022) ResBiotic Nutrition Inc, a microbiome-based nutrition company pioneering probiotics for gut, lung, and immune health, today announced new preclinical data from a study of resB™ Lung Support, the first science-backed probiotic and herbal supplement for lung health. The data presented today at Digestive Disease Week 2022 in San Diego, Calif., suggest that resB Lung Support works effectively against key inflammatory markers in the lungs.
"These important findings reaffirm the role of our proprietary blend of probiotic strains and bioactive botanical extracts in targeting the gut-lung axis,” said Founder and CEO Vivek Lal, MD, FAAP. “After studying the microbiome as it relates to lung health for more than a decade, we’re eager to present these initial data showing positive effects of resB on lung structure and function.”
Researchers investigated the effects of oral administration with resB to positively impact lung health by reducing inflammation and damage induced by a bacterial imbalance or dysbiosis. Results from in vitro models showed that oral supplementation with resB is associated with a decrease in MMP-9 inflammatory pathway activity, which is associated with tissue damage and neutrophilic inflammation. Additionally, in the in vivo models of dysbiosis and lung tissue damage, oral resB administration leads to improved lung structure and reduced neutrophilic inflammation.
“With the presentation of these preliminary findings for resB Lung Support, we are pleased to contribute to the growing body of evidence around the gut-lung axis and look forward to sharing complete results from this study on lung health and results from future studies supporting its role in lung, digestion, and immune function,” said Dr. Lal.
ResBiotic is conducting further clinical trials to test the effects of taking resB Lung Support formulation in human populations. Ongoing clinical trials are looking at the effects of resB in healthy people, smokers, and people with asthma; quality of life in patients with chronic obstructive pulmonary disease and non-cystic fibrosis bronchiectasis; and pneumonia incidence and prognosis in acute care settings.
Details of the presentation are as follows:
Poster Presentation: Probiotic and Herbal Blend Decreases Markers of Neutrophilic Inflammation in In Vitro and In Vivo Models of Proteobacteria-Induced Dysbiosis
Session Title: Prebiotics, Probiotics and Synbiotics in Health and Disease
Session Date/Time: May 21, 2022 from 12:30 PM to 1:30 PM
Poster Board Number: Sa1655
Location: San Diego Convention Center Poster Hall
Abstract Number: 3700698
Media Contact: email@example.com
About ResBiotic Nutrition, Inc:
ResBiotic is a first-in-class respiratory probiotics company pioneering science-backed supplements for gut, lung, and immune health. Founded and managed by physician-scientists, the company is the culmination of decades of research at the intersection of respiratory health and microbiome science. ResBiotic's first product, resB Lung Support, targets the gut-lung axis with a combination of clinically studied probiotic strains and bioactive botanicals. To learn more, visit www.resbiotic.com .
Digestive Disease Week®
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and virtual meeting from May 21-24, 2022. The meeting showcases more than 3,100 abstracts and hundreds of lectures on the latest advances in GI research, medicine, and technology. More information can be found at www.ddw.org.